Euclidean Capital LLC Rubius Therapeutics, Inc. Transaction History

Euclidean Capital LLC

  • $779 Million
  • Q1 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 16, 2021
SELL
$22.26 - $28.43 $284,727 - $363,648
-12,791 Closed
0 $0
Q1 2021

May 17, 2021
BUY
$8.02 - $32.01 $102,583 - $409,439
12,791 New
12,791 $339,000

Others Institutions Holding RUBY

# of Institutions
2
Shares Held
325
Call Options Held
0
Put Options Held
0
View Full List

About Rubius Therapeutics, Inc.

RUBY Quotes by TradingView
  • Ticker RUBY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,357,000
  • Description
  • Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...
More about RUBY
Track This Portfolio

Track Euclidean Capital LLC Portfolio

Follow Euclidean Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Euclidean Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Euclidean Capital LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email